



**BlueCross BlueShield
of Oklahoma**

If a conflict arises between a Clinical Payment and Coding Policy (“CPCP”) and any plan document under which a member is entitled to Covered Services, the plan document will govern. If a conflict arises between a CPCP and any provider contract pursuant to which a provider participates in and/or provides Covered Services to eligible member(s) and/or plans, the provider contract will govern. “Plan documents” include, but are not limited to, Certificates of Health Care Benefits, benefit booklets, Summary Plan Descriptions, and other coverage documents. BCBSOK may use reasonable discretion interpreting and applying this policy to services being delivered in a particular case. BCBSOK has full and final discretionary authority for their interpretation and application to the extent provided under any applicable plan documents.

Providers are responsible for submission of accurate documentation of services performed. Providers are expected to submit claims for services rendered using valid code combinations from Health Insurance Portability and Accountability Act (“HIPAA”) approved code sets. Claims should be coded appropriately according to industry standard coding guidelines including, but not limited to: Uniform Billing (“UB”) Editor, American Medical Association (“AMA”), Current Procedural Terminology (“CPT®”), CPT® Assistant, Healthcare Common Procedure Coding System (“HCPCS”), ICD-10 CM and PCS, National Drug Codes (“NDC”), Diagnosis Related Group (“DRG”) guidelines, Centers for Medicare and Medicaid Services (“CMS”) National Correct Coding Initiative (“NCCI”) Policy Manual, CCI table edits and other CMS guidelines.

Claims are subject to the code edit protocols for services/procedures billed. Claim submissions are subject to claim review including but not limited to, any terms of benefit coverage, provider contract language, medical policies, clinical payment and coding policies as well as coding software logic. Upon request, the provider is urged to submit any additional documentation.

Flow Cytometry

Policy Number: CPCPLAB001

Version 1.0

Plan Effective Date: Nov. 1, 2022

Description

BCBSOK has implemented certain lab management reimbursement criteria. Not all requirements apply to each product. Providers are urged to review Plan documents for eligible coverage for services rendered.

Reimbursement Information:

Flow cytometry immunophenotyping of cell surface markers **may be reimbursable** for any of the following conditions:

- a. Cytopenias, lymphomas, leukemia and lymphoproliferative disorders or myelodysplastic syndrome;
- b. B-cell monitoring for immunosuppressive disorders;
- c. T-cell monitoring for HIV infection and AIDS;
- d. Mast cell neoplasms;
- e. Paroxysmal nocturnal hemoglobinuria;
- f. Post-operative monitoring of members who have undergone organ transplantation;
- g. Plasma cell disorders;

- h. Primary Immunodeficiencies (PIDs), and PIDs involving T, NK;
- i. Hypercellular Hematolymphoid Disorders;
- j. Chronic Lymphocytic Leukemia (CLL);
- k. Chronic Myeloproliferative Disorders (CMPD);
- l. Minimal Residual Disease (MRD);
- m. Molar pregnancy;
- n. Primary Platelet Disorders, Non-neoplastic;
- o. Red Cell and White Cell Disorders, Non-neoplastic.

Flow cytometry immunophenotyping of cell surface markers **is not reimbursable** for any clinical condition not listed above.

The following reimbursement limitations will apply for flow cytometry:

- a. For flow cytometric immunophenotyping for the assessment of potential hematolymphoid neoplasia, use codes 88184-88189.
- b. Code 88184 should be used for the first marker, per specimen, and is reimbursable up to a maximum of two units per date of service.
- c. Code 88185 should be used for each additional marker and is reimbursable up to a maximum of 35 units, per date of service.
- d. In patients with a neoplasm with an established immunophenotype, subsequent tests for that neoplasm should be limited to diagnostically relevant markers.
- e. Codes 88187, 88188, and 88189 should not be used together in any combination. They are mutually exclusive and reimbursable as a single unit only.
- f. Codes 88187-88189 should not be used in conjunction with codes 86355, 86356, 86357, 86359, 86360, 86361, 86367.
- g. Use codes 86355, 86357, 86359, 86360, 86361, or 86367 for cell enumeration. These codes are reimbursable as single units only.

Bill Type Codes

012x	Hospital Inpatient (Medicare Part B only)
013x	Hospital Outpatient
014x	Hospital - Laboratory Services Provided to Non-patients
018x	Hospital - Swing Beds
021x	Skilled Nursing - Inpatient (Including Medicare Part A)
022x	Skilled Nursing - Inpatient (Medicare Part B only)
023x	Skilled Nursing - Outpatient
071x	Clinic - Rural Health
077x	Clinic - Federally Qualified Health Center (FQHC)
085x	Critical Access Hospital

Group 1 Codes

88182	Cell marker study
88184	Flowcytometry/ tc 1 marker
88185	Flowcytometry/tc add-on
88187	Flowcytometry/read 2-8
88188	Flowcytometry/read 9-15
88189	Flowcytometry/read 16 & >

Group 2: Quantitative Codes in immunology section

Group 2 Codes

86355	B cells total count
86356	Mononuclear cell antigen
86357	Nk cells total count
86359	T cells total count
86360	T cell absolute count/ratio
86361	T cell absolute count
86367	Stem cells total count

Procedure Codes

Codes
86355, 86356, 86357, 86359, 86360, 86361, 86367, 88182, 88184, 88185, 88187, 88188, 88189, 88199

References:

- Abraham, R. S., & Aubert, G. (2016). Flow Cytometry, a Versatile Tool for Diagnosis and Monitoring of Primary Immunodeficiencies. *Clin Vaccine Immunol*, 23(4), 254-271. doi:10.1128/cvi.00001-16
- Adan, A., Alizada, G., Kiraz, Y., Baran, Y., & Nalbant, A. (2017). Flow cytometry: basic principles and applications. *Crit Rev Biotechnol*, 37(2), 163-176. doi:10.3109/07388551.2015.1128876
- Brown, M., & Wittwer, C. (2000). Flow cytometry: principles and clinical applications in hematology. *Clin Chem*, 46(8 Pt 2), 1221-1229. Retrieved from <http://clinchem.aaccjnls.org/content/46/8/1221>
- Cosma, A., Nolan, G., & Gaudilliere, B. (2017). Mass cytometry: The time to settle down. *Cytometry A*, 91(1), 12-13. doi:10.1002/cyto.a.23032
- Davis, B. H., Holden, J. T., Bene, M. C., Borowitz, M. J., Braylan, R. C., Cornfield, D., . . . Stetler-Stevenson, M. (2007). 2006 Bethesda International Consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: medical indications. *Cytometry B Clin Cytom*, 72 Suppl 1, S5-13. doi:10.1002/cyto.b.20365
- Finak, G., Langweiler, M., Jaimes, M., Malek, M., Taghiyar, J., Korin, Y., . . . McCoy, J. P. (2016). Standardizing Flow Cytometry Immunophenotyping Analysis from the Human ImmunoPhenotyping Consortium. *Sci Rep*, 6, 20686. doi:10.1038/srep20686
- Fromm, J. R., Thomas, A., & Wood, B. L. (2009). Flow cytometry can diagnose classical Hodgkin lymphoma in lymph nodes with high sensitivity and specificity. *Am J Clin Pathol*, 131(3), 322-332. doi:10.1309/ajcpw3un9dyldspb
- Halder, M., Nath, S., & Jha, S. (2017). Flow Cytometry and Its Utility. *Chromosome Structure and Aberrations*, 109-126. Retrieved from https://link.springer.com/chapter/10.1007/978-81-322-3673-3_5
- Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., . . . Bast, R. C., Jr. (2007). American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. *J Clin Oncol*, 25(33), 5287-5312. doi:10.1200/jco.2007.14.2364

Locker, G. Y., Hamilton, S., Harris, J., Jessup, J. M., Kemeny, N., Macdonald, J. S., . . . Bast, R. C., Jr. (2006). ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. *J Clin Oncol*, 24(33), 5313-5327. doi:10.1200/jco.2006.08.2644

McKinnon, K. M. (2018). Flow Cytometry: An Overview. *Curr Protoc Immunol*, 120, 5.1.1-5.1.11. doi:10.1002/cpim.40

Novikov, N. D., Griffin, G. K., Dudley, G., Drew, M., Rojas-Rudilla, V., Lindeman, N. I., & Dorfman, D. M. (2019). Utility of a Simple and Robust Flow Cytometry Assay for Rapid Clonality Testing in Mature Peripheral T-Cell Lymphomas. *Am J Clin Pathol*, 151(5), 494-503. doi:10.1093/ajcp/aqy173

Paiva, B., Merino, J., & San Miguel, J. F. (2016). Utility of flow cytometry studies in the management of patients with multiple myeloma. *Curr Opin Oncol*, 28(6), 511-517. doi:10.1097/cco.0000000000000331

Porwit, A., van de Loosdrecht, A. A., Bettelheim, P., Brodersen, L. E., Burbury, K., Cremers, E., . . . Bene, M. C. (2014). Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS. *Leukemia*, 28(9), 1793-1798. doi:10.1038/leu.2014.191

Rawstron, A. C., Kreuzer, K. A., Soosapilla, A., Spacek, M., Stehlikova, O., Gambell, P., . . . Montserrat, E. (2018). Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. *Cytometry B Clin Cytom*, 94(1), 121-128. doi:10.1002/cyto.b.21595

Robinson, J. P., & Roederer, M. (2015). HISTORY OF SCIENCE. Flow cytometry strikes gold. *Science*, 350(6262), 739-740. doi:10.1126/science.aad6770

Verbsky, J., & Routes, J. (2018). Flow cytometry for the diagnosis of primary immunodeficiencies. Retrieved from https://www.uptodate.com/contents/flow-cytometry-for-the-diagnosis-of-primaryimmunodeficiencies?source=search_result&search=flow%20cytometry&selectedTitle=1~150

Wang, Z., Guo, M., Zhang, Y., Xu, S., Cheng, H., Wu, J., . . . Tang, G. (2019). The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation. *Int J Lab Hematol*, 41(5), 607-614. doi:10.1111/ijlh.13070

Policy Update History:

11/1/2022	New policy
-----------	------------